Oncolytic cancer therapy with a vaccinia virus strain.

In this study, the oncolytic efficacy of VG9 was evaluated. We examined in vitro replication and cytotoxicity, in vivo biodistribution, and antitumor effects in a B16 tumor model. The results revealed that VG9 replicated rapidly, but the cytotoxicity varied in different cell lines. Significant antitumor effects of VG9 were observed in a murine melanoma tumor model, and an antitumor cytotoxic T‑lymphocyte response induced by VG9 was also observed. The results indicated that the Chinese vaccinia strain VG9 holds promise in the construction of a recombinant vaccinia virus vector and as a potential therapeutic strategy in cancer treatment. PMID: 30365140 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research